Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2020 and Shareholders' Circular (the Notice).
The Notice has been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm. The Notice is also available on the Company's website at www.astrazeneca.com/agm.
The Company's Annual Report and Form 20-F Information 2019 was published on 3 March 2020.
The Notice is being despatched to shareholders today.
The meeting place for the Annual General Meeting (AGM) will be Leonardo Royal Hotel London Tower Bridge, 45 Prescot St, London, E1 8GP and the AGM will commence at 2.30 pm (BST) on 29 April 2020.
The Company continues to monitor the situation in relation to COVID-19 and will notify shareholders via our website, www.astrazeneca.com as soon as practicably possible if there are any changes to the AGM arrangements. Shareholders are reminded of their right to appoint the Chairman of the AGM, or any other person, as their proxy to attend the meeting and vote on their behalf.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
| Media Relations | ||
| Gonzalo Viña | +44 203 749 5916 | |
| Rob Skelding | Oncology | +44 203 749 5821 |
| Rebecca Einhorn | Oncology | +1 301 518 4122 |
| Matt Kent | BioPharmaceuticals | +44 203 749 5906 |
| Angela Fiorin | BioPharmaceuticals | +44 1223 344 690 |
| Jennifer Hursit | Other | +44 203 749 5762 |
| Christina Malmberg Hägerstrand | Sweden | +46 8 552 53 106 |
| Michele Meixell | US | +1 302 885 2677 |
| Investor Relations | ||
| Thomas Kudsk Larsen | +44 203 749 5712 | |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | BioPharmaceuticals (Cardiovascular, Metabolism) | +44 203 749 5711 |
| Nick Stone | BioPharmaceuticals (Renal) Environmental, Social and Governance | +44 203 749 5716 |
| Josie Afolabi | BioPharmaceuticals (Respiratory) | +44 203 749 5631 |
| Tom Waldron | Other medicines | +44 7385 033 717 |
| Craig Marks | Finance Fixed income | +44 7881 615 764 |
| Jennifer Kretzmann | Corporate access Retail investors | +44 203 749 5824 |
| US toll-free | +1 866 381 72 77 |
Christina Malmberg Hägerstrand
Presschef AstraZeneca AB och Norden Baltikum
+ 46 8 552 53 106
christina.malmberghagerstrand@astrazeneca.com